Engineering optimized N-glycosylation in the silkworm silkgland protein expression system

项目摘要 许多具有生物医学意义的蛋白质，包括抗体、细胞因子、抗凝剂、凝血 因子，其他的是糖蛋白。因此，对于可用于生产的系统存在很高的需求。 用于基础生物医学研究和直接临床应用的重组糖蛋白。不幸的是， 目前可用的重组蛋白生产系统可以生产高级真核糖蛋白， 真实的、相对均匀的碳水化合物侧链。的长期目标 这项建议是对家蚕进行基因工程改造，使其成为一个能够实现这些目标的系统。 重组糖蛋白生产的要求。大量研究表明， 作为一种高效的丝蛋白生产和分泌器官， 可以被工程化以有效地生产和分泌重组蛋白。然而，转基因蚕 尚未有效地用于重组糖蛋白生产， 丝腺的糖基化途径不能适当地糖基化外源的高等真核糖蛋白。 这项研究旨在将家蚕作为一种新的重组人免疫系统， 通过创建编码一组所需的高级真核酶的转基因家蚕来生产糖蛋白 为了“人源化”天然丝腺蛋白N-糖基化途径和重组人N-糖蛋白， 兴趣每个转基因将置于组织特异性Ser 1启动子的控制下，以靶向其表达。 表达至中部丝腺。 据我们所知，只有一个先前的报告，有效的基因工程的蛋白质 糖基化途径，包括B。森。我们将在取得初步成功的基础上， 糖工程改造B的蛋白质N-糖基化途径。森大力推进丝绸的使用 腺作为生物反应器用于重组糖蛋白的生产和分泌。这将产生净积极影响 在世界范围内发达国家和不发达国家的丝绸行业，允许增值产品 除了基本的丝之外， 纤维，从而显着提高了这个重要的生物制造平台的价值。 Jarvis和Fraser实验室已经证明了他们进行这项研究的能力， 出版记录。此外，在过去的15年里， 多年来，产生了大量相关的初步数据。这些领域中的互补技能 两个实验室，他们建立的工作关系，以及迄今为止获得的初步数据强烈表明， 可以顺利完成研究。

PROJECT SUMMARY Many biomedically significant proteins, including antibodies, cytokines, anticoagulants, blood clotting factors, and others are glycoproteins. Thus, there is a high demand for systems that can be used to produce recombinant glycoproteins for basic biomedical research and direct clinical applications. Unfortunately, few currently available recombinant protein production systems can produce higher eukaryotic glycoproteins with authentic, relatively homogeneous carbohydrate side chains at relatively low cost. The long-term objective of this proposal is to genetically engineer the silkworm, Bombyx mori, as a system that can fulfill these requirements for recombinant glycoprotein production. Numerous studies have shown that the silkworm silk gland, which has evolved for millions of years as a highly efficient silk protein production and secretion organ, can be engineered to efficiently produce and secrete recombinant proteins. However, transgenic silkworms have not yet been effectively used for recombinant glycoprotein production because the endogenous protein glycosylation pathways of the silk gland cannot properly glycosylate foreign, higher eukaryotic glycoproteins. The proposed research seeks to develop the silkworm as a novel system for recombinant human glycoprotein production by creating transgenic silkworms encoding a set of higher eukaryotic enzymes needed to “humanize” the native silk gland protein N-glycosylation pathway and recombinant human N-glycoproteins of interest. Each transgene will be placed under the control of the tissue-specific Ser1 promoter to target its expression to the middle silk gland. To our knowledge, there is only one prior report of the effective genetic engineering of a protein glycosylation pathway in any multicellular animal, including B. mori. We will build upon our initial success of glycoengineering the protein N-glycosylation pathway of B. mori to significantly advance the use of the silk gland as a bioreactor for recombinant glycoprotein production and secretion. This will have a net positive effect on silk industries in both developed and underdeveloped countries worldwide, allowing value added products important for human health to be produced in an economically feasible manner in addition to the basic silk fiber, thereby significantly increasing the value of this important biomanufacturing platform. The Jarvis and Fraser laboratories have a demonstrated ability to perform this research as shown by their publication records. In addition, they have been productively collaborating on related projects for the past 15 years, generating a significant amount of relevant preliminary data. The complementary skills available in these two labs, their established working relationship, and the preliminary data obtained to date strongly suggest the proposed research can be successfully completed.